VX15/2503 + avelumab
VX15/2503-04
Phase 2 small_molecule completed
Quick answer
VX15/2503 + avelumab for Carcinoma, Non-Small-Cell Lung is a Phase 2 program (small_molecule) at VACCINEX, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- VACCINEX, INC.
- Indication
- Carcinoma, Non-Small-Cell Lung
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed